Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 3 of 65 · 3077 articles
This study reports that an optimized Cycas revoluta leaf extract reduced colon inflammation and markers of oxidative stress in a rat model of ulcerative colitis, suggesting it could be a source of bioactive compounds...
The article offers an Ayurvedic framework for understanding and managing ulcerative colitis that may interest patients seeking complementary approaches and clinicians exploring integrative care. It emphasizes dietary and...
If true, a commonly available dietary change—drinking alkalinised filtered water—might modestly affect inflammatory markers and specific gut bacteria in people with IBD in remission, which could be of interest to...
Patients and clinicians may care because the investigational drug duvakitug reportedly sustained clinical and endoscopic benefits through 44 weeks in both ulcerative colitis and Crohn’s disease, which could represent a...
This report documents one‑year outcomes after fecal microbiota transplantation in four very ill children across several indications, including a child with Crohn’s disease and severe C.
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.
The paper identifies a metabolic pathway (HIF-1α–driven lactylation leading to ferroptosis) that may contribute to epithelial injury in ulcerative colitis and proposes quercetin as a candidate inhibitor—potentially...
This study identifies KCTD10 as a regulator of intestinal stem cell function and mucosal repair in experimental colitis, which could point to new mechanistic insights about why epithelial healing fails in some cases of...
If endometriosis is linked to other immune, allergic, or chronic pain conditions, people with endometriosis may benefit from broader evaluation and coordinated care beyond gynecology. The review suggests shared...
Perianal fistulizing Crohn's disease is a frequent, hard-to-treat complication; molecular and multiomic advances could lead to biomarkers that help choose better-targeted therapies and improve surgical–medical decision...
This trial tested a new monoclonal antibody directed at TLR3 in moderate-to-severe ulcerative colitis to see if it is safe and biologically active.
The study identifies a redox–inflammasome pathway (Nrf2 linked to NLRP3/IL‑1β) relevant to UC and shows that sulforaphane can modulate this axis in intestinal epithelial cells, highlighting a potential therapeutic target...
The gut microbiome and its metabolic pathways are areas of active research in IBD; this study suggests specific genera and predicted functions that could become candidate biomarkers or targets for follow-up studies.
Researchers engineered bispecific antibodies that block two inflammatory pathways (TL1A and IL-12/23p40) simultaneously, a strategy that could overcome limits of single-target therapies in IBD. The work is preclinical...
Parents and clinicians often worry about liver disease when children are diagnosed with Crohn's. This study suggests advanced liver fibrosis is uncommon at diagnosis, but elastography and fibrotic biomarkers can be...
This study suggests a relationship between higher ustekinumab trough concentrations and clinical remission in adults with Crohn’s disease, which could be relevant to patients and clinicians considering drug-level...
Noninvasive biomarkers that predict response to anti‑TNF drugs could help personalize treatment decisions and identify early who will achieve long‑term endoscopic remission.
Pyroptosis is a key inflammatory pathway that may drive or modulate IBD activity. Understanding and targeting it could lead to new treatments, but past trial setbacks mean patients should know translation is still...
The study identifies how secreted products from Lactobacillus brevis can selectively lower inflammatory gene expression in an intestinal epithelial cell model, pointing to microbiome-derived mechanisms that might become...
The study links microbiome metabolites to reduced epithelial inflammation and improved barrier function via AhR and cholinergic pathways—mechanisms relevant to IBD. This could guide future preclinical and therapeutic...
This work suggests a new experimental target (extracellular vimentin) that reduced inflammation, fibrosis-related markers, and necroptotic cell-death markers in mice and in cultured colon cells — processes that are...
People with ulcerative colitis may eventually have an oral small-molecule option that targets the TNF-α pathway instead of injectable biologics. Early-stage preclinical work suggests a new mechanism (allosteric MKK3...
This report describes early human evidence that an oral, gut-targeted PDE4 inhibitor (PALI-2108) may reduce intestinal inflammation and improve endoscopic findings in people with Crohn's disease and ulcerative colitis —...
If validated, differences in tissue QDPR could become a marker to help differentiate UC from CD and to indicate mucosal antioxidant/repair status, which may be relevant for disease monitoring and research into new...
Cure8 could only read part of this source from finance.yahoo.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Research and...
New Phase 2b maintenance data suggest a novel anti‑TL1A antibody may provide sustained symptom relief and mucosal improvement for some people with moderate-to-severe UC or CD — outcomes that matter because durable...
Early Phase 1b results suggest PALI-2108 may produce rapid improvements on endoscopy and calprotectin in very small Crohn’s and UC cohorts, which could matter if later trials confirm benefit and safety. The findings are...
Early-phase data suggest PALI-2108 reaches the ileum and colon and produced rapid reductions in endoscopic inflammation and fecal calprotectin in small Phase 1b cohorts—results that could matter if confirmed in larger...
If confirmed in later trials, a new TL1A‑targeting antibody could add a novel mechanism for patients with UC or Crohn’s who do not respond adequately to current therapies. Durable clinical and endoscopic responses over...
Phase 2a data suggest a combo approach may improve endoscopic remission versus Skyrizi alone, which could matter for future Crohn's treatment options and for patients who have failed prior advanced therapies.
This trial explores whether delivering sodium propionate directly to the colon can alter the gut microbiome and immune markers in people with Crohn’s disease and whether it offers similar or added benefits compared with...
Dietary patterns, especially ultra-processed food intake, are increasingly linked to Crohn's disease activity. This trial could provide randomized evidence on whether reducing ultra-processed foods prolongs remission in...
This trial is testing a novel stem-cell infusion approach aimed at treating Crohn’s disease and ulcerative colitis, so people with IBD may be interested in emerging cell-therapy options and safety data. Phase 1 studies...
An oral biologic study could offer a new treatment approach for people with moderate–severe ulcerative colitis; the trial is evaluating safety and multiple measures of disease activity including endoscopy and histology.
The study focuses on children newly diagnosed with Crohn's disease who start anti-TNF treatment and aims to identify biological and clinical markers tied to complete intestinal healing after one year; results could help...
Cure8 found this source from app.dealroom.co, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Fistula. Open the original article for the full details.
New Phase 2a data suggest a two‑drug combo from AbbVie may produce higher endoscopic remission than Skyrizi alone, which could matter for future treatment options and for patients who have failed prior advanced...
This preclinical study suggests a plant extract reduced inflammation and oxidative stress in a mouse model of ulcerative colitis and proposes molecular targets — an early step toward potential new treatments or research...
Biomarkers of gut barrier integrity and oxidative stress could reveal hidden inflammation, help predict disease progression, and indicate likely treatment response—steps toward more personalized IBD care.
Researchers identified a plant-derived compound that reduced inflammation, oxidative stress, and gut dysbiosis in a mouse model of ulcerative colitis; this could point to new mechanistic leads for future therapies...
The study identifies a new monocyte-surface RNA (Y RNAs) that appears higher in an exploratory IBD cohort and amplifies inflammatory signalling in cells and mice, which could point to new biomarker or therapeutic...
The paper points out that reused patient records and preprocessing choices can change how well gene-expression models appear to predict infliximab response. That matters because such biases could mislead researchers and...
The review identifies PPARγ as a key molecular hub in ulcerative colitis and compiles preclinical evidence that natural compounds can modulate PPARγ-related networks—suggesting possible new therapeutic directions that...
Patients on or considering infliximab may be interested because the paper identifies a possible molecular reason some people don’t respond and tests strategies that could, in principle, improve response to infliximab.
Intestinal fibrosis and strictures are a major unmet need in Crohn’s disease because current anti-inflammatory drugs often don’t reverse established scarring. A drug that limits or reverses fibrosis could reduce the need...
This preclinical study suggests clarithromycin may reduce colon inflammation in ulcerative colitis models and identifies Kv1.3 and the Th17/Treg balance as possible mechanisms — findings that could guide future...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. The original article is from Lipids in Health and Disease.
People with UC and their clinicians often consider infection risks when choosing biologic therapy. This study examines whether vedolizumab and anti‑TNF drugs differ in risk for C. difficile infection, a relevant...
